Lantern Pharma
LTRN
26 hedge funds and large institutions have $6.84M invested in Lantern Pharma in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 13 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0.17% more ownership
Funds ownership: 13.1% → 13.27% (+0.17%)
0% more funds holding
Funds holding: 26 → 26 (0)
15% less capital invested
Capital invested by funds: $8.06M → $6.84M (-$1.22M)
62% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 13
82% less call options, than puts
Call options by funds: $55K | Put options by funds: $311K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$78.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$68.6K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$26.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.5K |
| 5 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$5.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$13.4K |
| 2 |
BlackRock
New York
|
-$12.1K |
| 3 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$12K |
| 4 |
CC
Carlson Capital
Dallas,
Texas
|
-$10.8K |
| 5 |
JP Morgan Chase
New York
|
-$10.5K |
LTRN Hedge Fund Activity: Q3 2022 in Review
26 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q3 2022, worth a combined $6.84M — down 15% from $8.06M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LTRN positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 13 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $78.3K. The largest seller was Osaic Holdings, cutting an estimated $13.4K.
- 26 institutional investors held Lantern Pharma (LTRN) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $6.84M of Lantern Pharma stock for Q3 2022, down 15% quarter-over-quarter.
- 3 funds opened new Lantern Pharma positions in Q3 2022 and 2 closed out, a net change of +1 holder.
- The largest Lantern Pharma buyer in Q3 2022 was Susquehanna International Group, an estimated $78.3K added.
- The largest Lantern Pharma seller in Q3 2022 was Osaic Holdings, an estimated $13.4K sold.
Based on aggregated 13F filings for Q3 2022.